# A Study to Test the Blood Concentration of 4 Padsevonil Product Variants and the Effect of Food on Padsevonil

> **NCT04283136** · PHASE1 · WITHDRAWN · sponsor: **UCB Biopharma SRL**

## Conditions studied

- Healthy Participants
- Epilepsy

## Interventions

- **DRUG:** Padsevonil type 1 Tablet 200 mg
- **DRUG:** Padsevonil type 2 Tablet
- **DRUG:** Padsevonil type 3 Tablet
- **DRUG:** Padsevonil type 4 Tablet
- **DRUG:** Padsevonil type 5 Tablet

## Key facts

- **NCT ID:** NCT04283136
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-02-24
- **Primary completion:** 2020-05-22
- **Final completion:** 2020-05-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures
- **Last updated:** 2020-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04283136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04283136, "A Study to Test the Blood Concentration of 4 Padsevonil Product Variants and the Effect of Food on Padsevonil". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04283136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*